Vaccinex has completed its target enrollment in a Phase 2 clinical trial assessing the potential of the investigational antibody …
Articles by Alice Melão
One-time delivery of Voyager Therapeutics’ lead candidate gene therapy, VY-HTT01, effectively reduced the levels of the faulty gene responsible for…
The National Institute on Aging at the National Institutes of Health (NIH) has granted $12.6 million to Northwestern University to…
Short huntingtin (HTT) protein fibers precede the formation of larger deposits that accumulate in the brains of those affected by…
The European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to Roche’s investigational therapy RG6042 for…
SOM3355 — a medicine approved for high blood pressure and chest pain — is being tested in a Phase 2…
Adequate support and follow-up should be considered when implementing and designing pre-symptomatic genetic testing for Huntington’s disease, a study has…
Improved measures to accurately determine the effectiveness of treatments targeting Huntington’s disease are necessary, according to clinical neurologists and Huntington’s…
A new therapeutic strategy based on a small part of the huntingtin protein — which in a mutated form is…
Apathy is linked to physical, cognitive, and behavioral impairments in patients with Huntington’s disease, a study shows. The study, “…